Αρχική World News FDA Approves Vepdegestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer World News FDA Approves Vepdegestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer Από Ogkologos - 13 Μαΐου, 2026 344 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the VERITAC-2 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Airbrushed Magazines Hurt the Body Image of Young Women — Here’s... 19 Μαΐου, 2021 What Comes after NCI-MATCH? NCI’s New Precision Medicine Cancer Trials 6 Δεκεμβρίου, 2023 How I Navigated the Challenges of 2 Colorectal Cancer Diagnoses As... 6 Ιανουαρίου, 2022 Addressing the Challenges of Cancer Misinformation on Social Media 9 Σεπτεμβρίου, 2021 Φόρτωση περισσοτέρων HOT NEWS Noninferiority of OS with 3 Months Compared to 6 Months of... Implanted “Drug Factories” Deliver Cancer Treatment Directly to Tumors Biomarker Analyses in Patients with HER2-positive or HER2-low Gastric and Gastro-oesophageal... Reducing the Cancer Burden: Future Directions for NCI’s Cancer Control Research